While Compass Therapeutics Inc has underperformed by -0.66%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CMPX fell by -6.83%, with highs and lows ranging from $2.34 to $0.76, whereas the simple moving average jumped by 0.14% in the last 200 days.
On December 23, 2024, D. Boral Capital started tracking Compass Therapeutics Inc (NASDAQ: CMPX) recommending Buy. A report published by Leerink Partners on November 15, 2024, Downgraded its rating to ‘Market Perform’ for CMPX. Ladenburg Thalmann also Upgraded CMPX shares as ‘Buy’, setting a target price of $5 on the company’s shares in a report dated September 16, 2024. Jefferies Initiated an Buy rating on January 31, 2023, and assigned a price target of $8. Stifel initiated its ‘Buy’ rating for CMPX, as published in its report on January 27, 2023. H.C. Wainwright’s report from May 23, 2022 suggests a price prediction of $12 for CMPX shares, giving the stock a ‘Buy’ rating. Ladenburg Thalmann also rated the stock as ‘Buy’.
Analysis of Compass Therapeutics Inc (CMPX)
To gain a thorough understanding of Compass Therapeutics Inc’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -32.01% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 31.84, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and CMPX is recording an average volume of 486.68K. On a monthly basis, the volatility of the stock is set at 7.94%, whereas on a weekly basis, it is put at 9.30%, with a loss of -1.96% over the past seven days. Furthermore, long-term investors anticipate a median target price of $11.00, showing growth from the present price of $1.50, which can serve as yet another indication of whether CMPX is worth investing in or should be passed over.
How Do You Analyze Compass Therapeutics Inc Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 38.60%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 39.08% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
CMPX shares are owned by institutional investors to the tune of 39.08% at present.
